Guardant Health Inc (NASDAQ:GH) Shares Sold by MetLife Investment Advisors LLC

MetLife Investment Advisors LLC decreased its position in shares of Guardant Health Inc (NASDAQ:GH) by 24.4% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,515 shares of the company’s stock after selling 2,107 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Guardant Health were worth $500,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wisconsin Capital Management LLC acquired a new position in Guardant Health during the 1st quarter valued at approximately $1,687,000. Atika Capital Management LLC acquired a new position in Guardant Health during the 1st quarter valued at approximately $4,373,000. MYDA Advisors LLC acquired a new position in Guardant Health during the 1st quarter valued at approximately $920,000. Dynamic Technology Lab Private Ltd acquired a new position in Guardant Health during the 1st quarter valued at approximately $622,000. Finally, NumerixS Investment Technologies Inc acquired a new position in Guardant Health during the 1st quarter valued at approximately $3,140,000. Institutional investors own 69.15% of the company’s stock.

In related news, Chairman Amirali Talasaz sold 232,460 shares of the stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $65.60, for a total transaction of $15,249,376.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Helmy Eltoukhy sold 131,340 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $65.32, for a total transaction of $8,579,128.80. The disclosure for this sale can be found here. Insiders sold 757,322 shares of company stock worth $50,522,435 in the last quarter.

A number of research analysts have issued reports on the stock. Canaccord Genuity cut their price target on shares of Yamana Gold from C$5.50 to C$4.25 in a research note on Tuesday, April 16th. JPMorgan Chase & Co. set a €52.00 ($60.47) price target on shares of Vonovia and gave the company a “buy” rating in a research note on Friday, May 10th. Zacks Investment Research upgraded shares of Garrett Motion from a “sell” rating to a “hold” rating in a research note on Friday, May 10th. Bank of America set a $25.00 price objective on shares of Bed Bath & Beyond and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Cowen increased their price objective on shares of Guardant Health from $40.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 3rd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $83.50.

Shares of NASDAQ:GH traded up $1.34 during midday trading on Thursday, reaching $93.67. The company’s stock had a trading volume of 627,000 shares, compared to its average volume of 1,017,725. The firm has a market capitalization of $7.99 billion and a price-to-earnings ratio of -33.45. Guardant Health Inc has a twelve month low of $27.04 and a twelve month high of $106.58. The firm has a fifty day moving average price of $86.60.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.05. The business had revenue of $36.66 million during the quarter, compared to analyst estimates of $32.12 million. Equities analysts forecast that Guardant Health Inc will post -1.48 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Read More: How a Strangle Strategy is different from a Straddle Strategy

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.